Stocks · News reference
Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 400 percent decrease over earnings of $0.01 per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 11:34 AM
- Checked
- Aug 12, 2026, 11:34 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
Read original at benzingaArbutus Biopharma shares are trading higher after the company announced plans to commence a modified Dutch Auction tender offer to repurchase up to $230 million shares at no less than $5.00 per share and not more than $5.75 per share.
Read original at benzingaArbutus Biopharma Plans To Commence Modified Dutch Auction Tender Offer To Repurchase Up To $230M Of Common Shares At Purchase Price Of Between $5.00 And $5.75 Per Share In Cash
Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified "Dutch
Read original at benzinga